EUCTR2010-022395-31-ES进行中（未招募）不适用
A randomized open-label multicenter phase III trial of Melphalan and Dexamethasone (MDex) versus Bortezomib, Melphalan and Dexamethasone (BMDex) for untreated patients with systemic light-chain (AL) amyloidosis
E.M.N. - EUROPEAN MYELOMA NETWORK0 个研究点目标入组 110 人开始时间: 2012年5月21日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 110
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Histologic diagnosis of amyloidosis. 2. Genetic testing must be negative for transthyretin mutations associated with hereditary amyloidosis or immunohistochemistry of amyloid deposits must provide clear evidence of K or ? light chains in those who present with peripheral neuropathy or heart as the dominant organ involvement. 3. Not eligible for ASCT with melphalan 200 mg/m2 . Patients who are eligible for SCT with melphalan 200 mg/m2 but decline the procedure, can be enrolled in the study, but are stratified in a separate stratum before randomization. 4. Patients must be ? 18 years of age. 5. ECOG performance status 0,1 or 2. 6. Measurable disease; al least one of the following criteria: ? monoclonal protein >10 g/L in serum ? amyloid-forming (involved) FLC >75 mg/L with an abnormal K/? ratio ? difference between involved and uninvolved FLC >50 mg/L ? bone marrow with a clonal predominance 7. Symptomatic organ involvement 8. Hemoglobin ?11 g/dL, absolute neutrophil count ?1500/mcL, platelets ?140,000/mcL. 9. Total bilirubin <2.5 mg/dL, alkaline phosphatase <5 × u.l.n., ALT <3 × u.l.n.. 10. Estimated glomerular filtration rate (eGFR) by the MDRD formula >30 ml/min. 11. Only patients who are informed of the investigational nature of this study and sign and give written informed consent in accordance with institutional, national and European guidelines are eligible to participate. 12. Women must be either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control 13. Men must agree to use an acceptable method for contraception for the duration of the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 100
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •1. Amyloid-specific syndrome 2. Isolated soft tissue involvement. 3. Presence of non-AL amyloidosis. 4. Previous treatment for plasma cell disease. 5. Bone marrow plasma cells >30%. 6. Cardiac stage III disease: both cTnT > 0.035 ng/mL (or in place of cTnT the cTnI > 0.10 ng/mL) and simultaneous NT-proBNP >332 ng/L. 7. Repetitive ventricular arrhythmias on 24h Holter ECG in spite of anti-arrhythmic treatment or chronic atrial fibrillation 8. Supine systolic blood pressure <100 mmHg or symptomatic orthostatic hypotension or clinically important autonomic disease 9. Grade 3 sensory or grade 1 painful peripheral neuropathy. 10. Patients with AL who are eligible for ASCT with 200 mg/m2 of melphalan. These are patients <65 years of age, without cardiac involvement (determined according to the consensus criteria), with eGFR >51mL/min, left ventricular ejection fraction >45%, and bilirubin <2.0 mg/dL. 11. Pregnant or nursing women. 12. Clinically overt multiple myeloma with lytic bone lesions 13. Patients with uncontrolled infection or active malignancy with the exception of adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease-free for 5 years. 14. Patients with medically documented cardiac syncope, uncompensated NYHA Class 3 or 4 congestive heart failure, or myocardial infarction within the previous 6 months are not eligible. 15. HIV positive. 16. Patients with serious medical or psychiatric illness likely to interfere with participation in this clinical study. 17. Patients with hypersensitivity to bortezomib, boron or mannitol.
研究者
相似试验
进行中（未招募）
1 期
A randomized open-label multicenter phase III trial of Melphalan and Dexamethasone (MDex) versus Bortezomib, Melphalan and Dexamethasone (BMDex) for untreated patients with systemic light-chain (AL) amyloidosisAL AmyloidosisMedDRA version: 14.1Level: HLGTClassification code 10035227Term: Plasma cell neoplasmsSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2010-022395-31-DKE.M.N. - EUROPEAN MYELOMA NETWORK110
已完成
3 期
An international trial with a new standard of care for patients with AL amyloidosis.ntreated systemic light chain amyloidosisAmyloidUntreated systemic light chain amyloidosisCancer - MyelomaACTRN12611000561987Australasian Leukaemia and Lymphoma Group (ALLG)110
进行中（未招募）
不适用
MDex vs BMDex in systemic light-chain (AL) amyloidosis [abnormal condition of depositing proteins known as amyloid in tissues and organs of the body]Systemic light-chain (AL) amyloidosisMedDRA version: 14.0Level: PTClassification code 10002022Term: AmyloidosisSystem Organ Class: 10021428 - Immune system disordersEUCTR2010-022395-31-GBEuropean Myeloma Network110
进行中（未招募）
1 期
Clinical trial of Melphalan and Dexamethasone versus Bortezomib, Melphalan and Dexamethasone for untreated patients with systemic light-chain (AL) amyloidosisAL amyloidosisMedDRA version: 14.1Level: PTClassification code 10002022Term: AmyloidosisSystem Organ Class: 10021428 - Immune system disordersEUCTR2010-022395-31-DEEuropean Myeloma Network110
进行中（未招募）
不适用
A randomized open-label multicenter phase III trial of Melphalan and Dexamethasone (MDex) versus Bortezomib, Melphalan and Dexamethasone (BMDex) for untreated patients with systemic light-chain (AL) amyloidosisAL AmyloidosisMedDRA version: 13.1Level: HLGTClassification code 10035227Term: Plasma cell neoplasmsSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2010-022395-31-SEE.M.N. - EUROPEAN MYELOMA NETWORK110